Scholarlink

<p>Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare and severely disabling genetic disorder affecting approximately one in two million individuals worldwide. It is characterised by progressive endochondral heterotopic ossification (HO), in which ectopic cartilage formation precedes and directs subsequent bone formation within muscles, tendons, and ligaments. Activating mutations in the <i>ACVR1</i> gene—most commonly the R206H variant—cause dysregulated bone morphogenetic protein (BMP) signaling through both SMAD-dependent and SMAD-independent pathways, leading to inappropriate osteogenic differentiation. Clinically, FOP presents with congenital great toe malformations and recurrent, painful flare-ups that progressively restrict mobility and cause complications such as thoracic insufficiency, ankylosis, and hearing loss. Early genetic diagnosis is critical to avoid iatrogenic harm. Current treatments rely on corticosteroids and NSAIDs, while Palovarotene—a selective retinoic acid receptor gamma agonist approved by the FDA in 2023—marks a major therapeutic advance despite safety limitations. Our review integrates recent breakthroughs, including Phase 3 Garetosmab results and ongoing trials of STOPFOP, INCB000928, and IPN60130, alongside emerging insights into fibro-adipogenic progenitors and molecular mechanisms of HO. Incorporation of regional case analyses from India, together with global data, strengthens the clinical relevance for low- and middle-income regions where FOP remains underreported. This comprehensive review provides the most current translational perspective on FOP, highlighting the alarming need for continued innovation to improve patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fibrodysplasia ossificans progressiva: from clinical complexity to therapeutic opportunity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Amrita Chakraborty,
  • Uday Sankar Chakrabarty,
  • Mainak Mal,
  • Susanta Paul,
  • Dibya Sinha,
  • Arvind Kumar,
  • Nilanjan Sarkar

摘要

Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare and severely disabling genetic disorder affecting approximately one in two million individuals worldwide. It is characterised by progressive endochondral heterotopic ossification (HO), in which ectopic cartilage formation precedes and directs subsequent bone formation within muscles, tendons, and ligaments. Activating mutations in the ACVR1 gene—most commonly the R206H variant—cause dysregulated bone morphogenetic protein (BMP) signaling through both SMAD-dependent and SMAD-independent pathways, leading to inappropriate osteogenic differentiation. Clinically, FOP presents with congenital great toe malformations and recurrent, painful flare-ups that progressively restrict mobility and cause complications such as thoracic insufficiency, ankylosis, and hearing loss. Early genetic diagnosis is critical to avoid iatrogenic harm. Current treatments rely on corticosteroids and NSAIDs, while Palovarotene—a selective retinoic acid receptor gamma agonist approved by the FDA in 2023—marks a major therapeutic advance despite safety limitations. Our review integrates recent breakthroughs, including Phase 3 Garetosmab results and ongoing trials of STOPFOP, INCB000928, and IPN60130, alongside emerging insights into fibro-adipogenic progenitors and molecular mechanisms of HO. Incorporation of regional case analyses from India, together with global data, strengthens the clinical relevance for low- and middle-income regions where FOP remains underreported. This comprehensive review provides the most current translational perspective on FOP, highlighting the alarming need for continued innovation to improve patient outcomes.